Abstract:Abstract Glioblastoma (GBM) is considered highly radioresistant. To improve the efficacy of GBM radiotherapy, one approach is the addition of a targeted radiosensitizer, which requires an understanding of the molecules that determine GBM radioresponse. Along these lines, PRMT5 is a type II arginine methyltransferase that symmetrically dimethylates histone and non-histone substrates to regulate chromatin structure and mRNA splicing, two parameters that can influence radiosensitivity. As an initial test of PRMT5 as a target for GBM radiosensitization, PRMT5 knockdown using siRNA was shown to increase the in vitro radiosensitivity of U251 GBM cells. PRMT5 was then targeted using the small molecule inhibitor LLY-283, which penetrates the blood brain barrier. Exposure of U251 cells to LLY-283 (24h) reduced the levels of symmetric dimethylated arginine as determined by western blot, indicating an inhibition of PRMT5 activity. Based on clonogenic analysis, LLY-283 exposure beginning 1h prior to irradiation significantly enhanced the radiosensitivity of U251 cells. Whereas treatment of the normal fibroblast cell line MRC9 with LLY-283 reduced PRMT5 activity, no effect was detected on radiosensitivity, suggesting tumor cell selective radiosensitization. As an initial investigation of the radiosensitizing mechanism, U251 were treated with LLY-283 1h prior irradiation (2Gy) and the number of γH2AX foci, marker for DNA double strand breaks (DSBs), was determined. Whereas LLY-283 had no effect on the initial level of radiation-induced γH2AX foci, the dispersal of foci was significantly delayed in LLY-283 treated cells. These results suggest that LLY-283 inhibits the repair of radiation-induced DSBs. The neutral comet assay, an alternative measure of radiation-induced DSBs showed that LLY-283 delivered 1h prior irradiation (10Gy) significantly increased the comet tail moment detected at 6 and 24h as compared to 10Gy only, consistent with an inhibition of DSB repair. Based on these two approaches LLY-283-induced radiosensitization appears to be mediated by an inhibition of DSB repair. Extending these studies to GBM stem-like cell lines (GSCs) showed that LLY-283 inhibited PRMT5 activity and when delivered 1h prior to irradiation enhanced radiosensitivity. Analysis of γH2AX foci showed a delay in foci dispersal in LLY-283 treated cells consistent with an inhibition of DSB repair. Because a 1h LLY-283 pretreatment was sufficient for the inhibition of DSB repair and enhanced radiosensitivity, it appears that the radiosensitization was primarily the result of altered chromatin function rather than changes in gene expression due to alternative mRNA splicing. Altogether, these results suggest targeting PRMT5 as a potential strategy for enhancing the radiosensitivity of GBMs. Citation Format: Charlotte M. Degorre, Steven Lohard, Philip J. Tofilon. Targeting prmt5 inhibits DNA repair and enhances the radiosensitivity of GBM cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2406.

Phragmunis a suppresses glioblastoma through the regulation of MCL1-FBXW7 by blocking ELK1-SRF complex-dependent transcription

Eucalyptal A inhibits glioma by rectifying oncogenic splicing of MYO1B mRNA via suppressing SRSF1 expression

Identification of Imidazo[4,5-C]pyridin-2-one Derivatives As Novel Src Family Kinase Inhibitors Against Glioblastoma.

Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway

Synergistic antitumor effects of Phlorizin and Temozolomide in glioblastoma: Mechanistic insights and molecular targeting

Pharmacological inhibition of the ubiquitin-specific protease 8 effectively suppresses glioblastoma cell growth

Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O6-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma

Β-Elemene Inhibits Proliferation of Human Glioblastoma Cells Through the Activation of Glia Maturation Factor Β and Induces Sensitization to Cisplatin.

PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma

PT109, a novel multi-kinase inhibitor suppresses glioblastoma multiforme through cell reprogramming: Involvement of PTBP1/PKM1/2 pathway

Galangin (GLN) Suppresses Proliferation, Migration, and Invasion of Human Glioblastoma Cells by Targeting Skp2-Induced Epithelial–Mesenchymal Transition (EMT)

Guggulsterone inhibits migration and invasion through proteasomal and lysosomal degradation in human glioblastoma cells

Myeloid cells coordinately induce glioma cell-intrinsic and cell-extrinsic pathways for chemoresistance via GP130 signaling

Characterizing Cell Stress and GRP78 in Glioma to Enhance Tumor Treatment

Abstract 2406: Targeting prmt5 inhibits DNA repair and enhances the radiosensitivity of GBM cells

CCL2-targeted ginkgolic acid exerts anti-glioblastoma effects by inhibiting the JAK3-STAT1/PI3K-AKT signaling pathway

O-GlcNAcylation of melanophilin enhances radiation resistance in glioblastoma via suppressing TRIM21 mediated ubiquitination

EGFR/EGFRvIII remodels the cytoskeleton via epigenetic silencing of AJAP1 in glioma cells

A Tropomyosin-Like Meretrix Meretrix Linnaeus Polypeptide Inhibits the Proliferation and Metastasis of Glioma Cells Via Microtubule Polymerization and FAK/Akt/MMPs Signaling.

Loss of PTPRS elicits potent metastatic capability and resistance to temozolomide in glioblastoma

PSMG3‐AS1 enhances glioma resistance to temozolomide via stabilizing c‐Myc in the nucleus